Abstract Voriconazole is commonly administered for a long period to patients receiving immunosuppressive therapy. Although voriconazole potentially induces skin cancers in association with sun exposure, this has not yet been examined in detail in a single ethnic patient group. Therefore, the present study investigated the risk of developing squamous cell carcinoma (SCC) in Japanese patients with voriconazole‐related actinic keratosis (AK) and the prognosis of Japanese patients with voriconazole‐related SCC. We retrospectively examined 37 Japanese patients with AK, including five voriconazole‐treated patients (mean age, 57.9??±??16.3??years) and 32 non‐treated patients (74.9??±??9.2??years), and 18 Japanese patients with SCC, including four voriconazole‐treated patients (55.4??±??16.7??years) and 14 non‐treated patients (74.1??±??10.7??years). Among the 37 patients with AK, SCC developed in five, including four with a history of treatment with both voriconazole and immunosuppressive agents, independent of AK progression. In these four patients, the mean period from the diagnosis of AK to that of SCC was 13.8??±??11.6??months. Kaplan––Meier analyses showed that the risk of developing SCC was significantly higher in patients with both voriconazole and immunosuppressants/corticosteroid‐treated patients with AK than in non‐voriconazole‐treated patients with AK (the Log‐rank test, p?
展开▼
机译：摘要 伏立康唑通常用于接受免疫抑制治疗的患者。尽管伏立康唑可能与日晒有关诱发皮肤癌，但尚未在单个种族患者群体中对此进行详细检查。因此，本研究调查了日本伏立康唑相关光化性角化病（AK）患者发生鳞状细胞癌（SCC）的风险以及日本伏立康唑相关鳞状细胞癌患者的预后。我们回顾性检查了 37 例日本 AK 患者，包括 5 例伏立康唑治疗患者（平均年龄，57.9？？±??16.3??年）和 32 名未接受治疗的患者 （74.9？？±??9.2??年）和 18 例日本鳞状细胞癌患者，包括 4 例伏立康唑治疗患者 （55.4？？±??16.7??年）和 14 名未经治疗的患者 （74.1？？±??10.7??年）。在 37 例 AK 患者中，有 5 例发生鳞状细胞癌，其中 4 例有伏立康唑和免疫抑制剂治疗史，与 AK 进展无关。在这4例患者中，从诊断为AK到诊断为SCC的平均时间为13.8？？±??11.6??月份。Kaplan--Meier 分析显示，伏立康唑和免疫抑制剂/皮质类固醇治疗的 AK 患者发生鳞状细胞癌的风险显著高于未接受伏立康唑治疗的 AK 患者（Log-rank 检验，p？0.001）。分析还显示，伏立康唑和免疫抑制剂/皮质类固醇治疗的鳞状细胞癌患者的死亡率明显高于未接受伏立康唑治疗的鳞状细胞癌患者（p？=？？0.018）. 本研究结果表明，伏立康唑相关AK先于皮肤鳞状细胞癌的发生，伏立康唑相关鳞状细胞癌在免疫抑制条件下导致预后不良。
展开▼
